OLFM4 (Olfactomedin-4) Gene Expression and Its Significance in Prostate Cancer Progression: A brief update on clinical implications

Background: Prostate cancer (PCa) remains the most frequently diagnosed solid malignancy among men worldwide. While localized diseases carry a favorable prognosis, a substantial subset progresses to castration-resistant prostate cancer (CRPC) and metastatic disease. Current biomarkers, most notably prostate-specific antigen (PSA), are insufficient for risk stratification, particularly in intermediate-risk and PSA-gray-zone cases. The OLFM4 (olfactomedin-4) gene, encoding a secreted olfactomedin-domain glycoprotein, has emerged as a candidate tumor suppressor in the prostate, though its role remains underrecognized in the urologic oncology literature. Evidence Synthesis: This review synthesizes findings from human tissue genetics, epigenetic profiling, knockout mouse models, cell-based gain/loss-of-function studies, and public transcriptomic cohort analyses. Convergent lines of evidence establish that OLFM4, located at 13q14.3, a cytogenetic region subject to frequent loss of heterozygosity in PCa, is silenced through complementary genetic deletion and promoter CpG hypermethylation, with loss correlating inversely with Gleason score, biochemical recurrence, and metastatic progression. The Olfm4⁻/⁻ mouse spontaneously develops prostatic intraepithelial neoplasia (PIN) and adenocarcinoma, and crossing with the TRAMP model accelerates lethal progression. At the molecular level, OLFM4 exerts tumor-suppressive effects by (i) directly binding and inhibiting cathepsin D and blocking the SDF-1/CXCR4-AKT invasive axis; (ii) interacting with Sonic Hedgehog (SHH) and restraining hedgehog signaling; and (iii) maintaining prostate epithelial differentiation such that its loss derepresses WNT/APC/MYC signaling in stem/progenitor-like compartments, creating a therapeutically exploitable MYC-addicted state. Conclusions: OLFM4 occupies a well-supported position as a 13q14.3 candidate tumor suppressor in prostate cancer, silenced by deletion and methylation, whose loss facilitates EMT, hedgehog/Wnt/Myc pathway activation, and eventual CRPC progression. Incorporating OLFM4 IHC or 13q14 FISH/CNV assessment into needle-biopsy risk stratification, as an adjunct to, not a replacement for, Gleason grading and genomic classifiers, represents the most actionable near-term translational path.